TW200700398A - Substituted n-sulfonylaminophenylethyl-2-phenoxyacetamide compounds - Google Patents

Substituted n-sulfonylaminophenylethyl-2-phenoxyacetamide compounds

Info

Publication number
TW200700398A
TW200700398A TW095108023A TW95108023A TW200700398A TW 200700398 A TW200700398 A TW 200700398A TW 095108023 A TW095108023 A TW 095108023A TW 95108023 A TW95108023 A TW 95108023A TW 200700398 A TW200700398 A TW 200700398A
Authority
TW
Taiwan
Prior art keywords
alkyl
alkoxy
hydroxy
halo
halogen atom
Prior art date
Application number
TW095108023A
Other languages
Chinese (zh)
Inventor
Takeshi Hanazawa
Misato Hirano
Tadashi Inoue
Satoshi Nagayama
Kazunari Nakao
Yuji Shishido
Hirotaka Tanaka
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TW200700398A publication Critical patent/TW200700398A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

This invention provides a compound of the formula (I): wherein R1 represents (C1-C6)alkyl; R2 represents a hydrogen atom, a halogen atom, a hydroxy group, (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy(C1-C6)alkyl, (C1-C6)alkoxy-(C1-C6)alkyl or halo(C1-C6)alkyl; R3 represents a halogen atom, (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy(C1-C6)alkoxy, (C1-C6)alkoxy-(C1-C6)alkyl, (C1-C6)alkoxy-(C1-C6)alkoxy, halo(C1-C6)alkyl, (C1-C6)alkylthio, (C1-C6)alkylsulfinyl, (C1-C6)alkylsulfonyl, [(C1-C6)alkyl]NH-, or[(C1-C6)alkyl]2N-; R4 represents a halogen atom, (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy, hydroxy(C1-C6)alkoxy, (C1-C6)alkoxy-(C1-C6)alkyl, (C1-C6)alkoxy-(C1-C6)alkoxy, [(C1-C6)alkyl]NH-, or [(C1-C6)alkyl]2N-; R5 represents a halogen atom, (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy(C1-C6)alkoxy, (C1-C6)alkoxy-(C1-C6)alkyl, (C1-C6)alkoxy-(C1-C6)alkoxy, halo(C1-C6)alkyt, (C1-C6)alkylthio, (C1-C6)alkylsulfinyl, (C1-C6)alkylsulfonyl, [(C1-C6)alkyl]NH-, [(C1-C6) alkyl]2N-, H2N-(C1-C6)alkoxy, (C1-C6)alkyl-NH-(C1-C6)alkoxy, [(C1-C6)alkyl]2N(C1-C6)alkoxy, H2N-(C1-C6)alkoxy-(C1-C6)alkyl,(C1-C6)alkyl-NH-(C1-C6)alkoxy-(C1-C6)alkyl, or [(C1-C6)alkyl]2N(C1-C6)alkoxy-(C1-C6)alkyl; and * indicates a chiral centre; or a pharmaceutically acceptable salt or solvate thereof. These compounds are useful for the treatment of disease conditions caused by overactivation of VR1 receptor such of pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.
TW095108023A 2005-03-10 2006-03-09 Substituted n-sulfonylaminophenylethyl-2-phenoxyacetamide compounds TW200700398A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66097805P 2005-03-10 2005-03-10

Publications (1)

Publication Number Publication Date
TW200700398A true TW200700398A (en) 2007-01-01

Family

ID=36297248

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095108023A TW200700398A (en) 2005-03-10 2006-03-09 Substituted n-sulfonylaminophenylethyl-2-phenoxyacetamide compounds

Country Status (16)

Country Link
US (1) US7566739B2 (en)
EP (1) EP1858865B1 (en)
JP (1) JP4906839B2 (en)
AR (1) AR052938A1 (en)
AT (1) ATE443056T1 (en)
CA (1) CA2600409C (en)
DE (1) DE602006009231D1 (en)
DO (1) DOP2006000060A (en)
ES (1) ES2331153T3 (en)
GT (1) GT200600107A (en)
MX (1) MX2007011105A (en)
NL (1) NL1031335C2 (en)
PE (1) PE20061163A1 (en)
TW (1) TW200700398A (en)
UY (1) UY29412A1 (en)
WO (1) WO2006095263A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001876A (en) 1996-07-24 1999-12-14 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
EP1861357B1 (en) * 2005-03-19 2013-04-24 Amorepacific Corporation Novel compounds or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
WO2007120012A1 (en) * 2006-04-19 2007-10-25 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
AU2007277519B2 (en) 2006-07-27 2011-12-22 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
EP2238105B1 (en) 2008-01-28 2014-04-16 Amorepacific Corporation Novel compounds as vanilloid receptor antagonists
WO2009132050A2 (en) 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
JP5438103B2 (en) 2008-07-02 2014-03-12 アモーレパシフィック コーポレイション Novel compounds as vanilloid receptor antagonists, isomers or pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing the same
CA2731769C (en) 2008-07-21 2013-09-10 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
JP2013518085A (en) 2010-02-01 2013-05-20 ノバルティス アーゲー Pyrazolo [5,1b] oxazole derivatives as CRF-1 receptor antagonists
JP5748777B2 (en) 2010-02-02 2015-07-15 ノバルティス アーゲー Cyclohexylamide derivatives as CRF receptor antagonists
KR101893751B1 (en) 2010-07-16 2018-09-03 애브비 아일랜드 언리미티드 컴퍼니 Process for preparing antiviral compounds
BR112013001138A2 (en) 2010-07-16 2016-07-05 Abbvie Inc phosphine binders for catalytic reactions
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
WO2018005830A1 (en) 2016-06-29 2018-01-04 Otonomy, Inc. Triglyceride otic formulations and uses thereof
US20200039922A1 (en) * 2016-10-05 2020-02-06 Afecta Pharmaceuticals, Inc. High mobility group b1 protein inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810716A (en) 1986-04-11 1989-03-07 Warner-Lambert Company Diarylalkanoids having activity as lipoxygenase inhibitors
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
MX226123B (en) 1999-09-17 2005-02-07 Millennium Pharm Inc BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa.
IL148698A0 (en) 1999-09-17 2002-09-12 Cor Therapeutics Inc INHIBITORS OF FACTOR Xa
US6376515B2 (en) 2000-02-29 2002-04-23 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor Xa
DE60120421T2 (en) * 2000-08-21 2006-12-28 Pacific Corp. NEW (THIO) UREA CONNECTIONS AND MEDICINAL COMPOSITIONS CONTAINING THEM
AU2001280229B2 (en) * 2000-08-21 2006-12-07 Pacific Corporation Novel thiourea derivatives and the pharmaceutical compositions containing the same
RU2296119C2 (en) 2001-10-04 2007-03-27 Новартис Аг Cyanoacetyl compounds, method for their preparing and their using (variants), composition and method for control of parasites
EP1505968A1 (en) 2002-05-13 2005-02-16 Eli Lilly And Company Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
KR100556158B1 (en) * 2002-10-17 2006-03-06 (주) 디지탈바이오텍 Novel N-hydroxy thiourea, urea and amide compounds and the pharmaceutical compositions containing the same
KR100707123B1 (en) * 2003-07-02 2007-04-16 그뤼넨탈 게엠베하 4-methylsulfonylaminophenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical composition containing the same
US20050085449A1 (en) 2003-10-15 2005-04-21 Dalton James T. Haloacetamide and azide substituted compounds and methods of use thereof
US7417169B2 (en) 2003-10-24 2008-08-26 Kissei Pharmaceutical Co., Ltd. Amino alcohol derivatives, medicinal composition containing the same, and use of these
CN101087771A (en) * 2004-11-10 2007-12-12 辉瑞大药厂 Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds

Also Published As

Publication number Publication date
EP1858865A1 (en) 2007-11-28
NL1031335A1 (en) 2006-09-12
CA2600409C (en) 2011-07-05
NL1031335C2 (en) 2007-01-23
DE602006009231D1 (en) 2009-10-29
WO2006095263A8 (en) 2007-11-08
JP4906839B2 (en) 2012-03-28
US7566739B2 (en) 2009-07-28
ATE443056T1 (en) 2009-10-15
JP2008532994A (en) 2008-08-21
AR052938A1 (en) 2007-04-11
PE20061163A1 (en) 2006-10-27
GT200600107A (en) 2006-12-26
WO2006095263A1 (en) 2006-09-14
US20060205980A1 (en) 2006-09-14
UY29412A1 (en) 2006-10-31
EP1858865B1 (en) 2009-09-16
CA2600409A1 (en) 2006-09-14
DOP2006000060A (en) 2006-09-30
MX2007011105A (en) 2007-10-08
ES2331153T3 (en) 2009-12-22

Similar Documents

Publication Publication Date Title
TW200700398A (en) Substituted n-sulfonylaminophenylethyl-2-phenoxyacetamide compounds
EP2298734A3 (en) Cyclobutyl amine derivatives
TW200621694A (en) Substituted n-sulfonylaminobenzyl-2-phenoxyacetamide compounds
AP1822A (en) Substituted pyridinones as modulators of P38 MAP kinase.
TW200517109A (en) Substituted pyridinones
RS20050732A (en) Substituted pyrimidinones
MX2009004096A (en) Talarazole metabolites.
TW200716528A (en) Cyclopropanecarboxamide derivatives
WO2006011050A3 (en) Pyridine derivatives
MXPA05012678A (en) CRYSTALLINE FORM OF beta2.
UA85576C2 (en) Tetrazole compounds and their use as metabotropic glutamate receptor antagonits
TW200613243A (en) Novel compounds
MX2008001606A (en) Substituted piperazines as metabotropic glutamate receptor antagonists.
EP2966065A3 (en) Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
TW200806311A (en) Neuropeptide-2 receptor-agonists
TW200740787A (en) (6-Fluoro-benzo[1,3]dioxolyl)-morpholin-4-yl-methanones
MXPA06009475A (en) Quinazoline derivatives and therapeutic use thereof.
WO2006057922A3 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
WO2008050199A8 (en) Substituted phenylmethyl bicyclocarboxyamide compounds
MY140235A (en) New benzimidazole derivatives
WO2008059370A8 (en) Substituted bicyclocarboxyamide compounds
TW200639156A (en) New compounds
PL1831202T3 (en) Pyrrolinidium derivatives as m3 muscarinic receptors
TW200716547A (en) Piperidin-4-yl-amide derivatives
MXPA05013151A (en) 3-fluoro-piperidines as nmda/nr2b antagonists.